Effect of aspirin on cancer chemoprevention in Japanese patients with type 2 diabetes: 10-year observational follow-up of a randomized controlled trial

Diabetes Care

Volumn 41, Issue 8, 2018, Pages 1757-1764

  Okada, Sadanori ^a   Morimoto, Takeshi ^b   Ogawa, Hisao ^c   Sakuma, Mio ^b   Matsumoto, Chisa ^b   Soejima, Hirofumi ^d   Nakayama, Masafumi ^e   Doi, Naofumi ^f   Jinnouchi, Hideaki ^g   Waki, Masako ^h   Masuda, Izuru ⁱ   Saito, Yoshihiko ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^d KUMAMOTO UNIVERSITY   (Japan)

^e Nakayama Cardiovascular Clinic   (Japan)

^f Nara Prefecture Western Medical Center   (Japan)

^g Jinnouchi Hospital Diabetes Care Center   (Japan)

^h SHIZUOKA CITY SHIMIZU HOSPITAL   (Japan)

ⁱ Takeda Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; AGED; ATHEROSCLEROSIS; CANCER INCIDENCE; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CHEMOPROPHYLAXIS; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DIABETIC PATIENT; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; JAPANESE (PEOPLE); LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SEX; SMOKING; CLINICAL TRIAL; COMPLICATION; INCIDENCE; JAPAN; MIDDLE AGED; NEOPLASM; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; CARDIOVASCULAR DISEASES; CHEMOPREVENTION; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; JAPAN; MALE; METFORMIN; MIDDLE AGED; NEOPLASMS;

EID: 85052992209     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc18-0368     Document Type: Conference Paper

References (40)

1. Ministry of Health, Labour and Welfare. Outline of vital statics in 2015 [Internet]. Available from http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai15/index.html. Accessed 1 September 2017
2. Nakamura J, Kamiya H, Haneda M, et al. Causes of death in Japanese patients with diabetes based on the results of a survey of 45, 708 cases during 2001-2010: report of the Committee on Causes of Death in Diabetes Mellitus. J Diabetes Investig 2017; 8:397-410
3. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995; 273:1605-1609
4. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005; 97:1679-1687
5. Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006; 49:2819-2823
6. Mitri J, Castillo J, Pittas AG. Diabetes and risk of Non-Hodgkin's lymphoma: a meta-analysis of observational studies. Diabetes Care 2008; 31:2391-2397
7. Noto H, Tsujimoto T, Sasazuki T, Noda M. Significantly increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Endocr Pract 2011; 17:616-628
8. Noto H, Osame K, Sasazuki T, Noda M. Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan. J Diabetes Complications 2010; 24:345-353
9. Kasuga M, Ueki K, Tajima N, et al. Report of the JDS/JCA Joint Committee on Diabetes and Cancer. Diabetol Int 2013; 4:81-96
10. Rao Kondapally Seshasai S, Kaptoge S, Thompson A, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364:829-841
11. Thun MJ, Namboodiri MM, Heath CW Jr Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325:1593-1596
12. Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998; 7:97-102
13. Jacobs EJ, Rodriguez C, Mondul AM, et al. A large cohort study of aspirin and other non-steroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 2005; 97: 975-980
14. Rothwell PM, Wilson M, Elwin CE, et al. Longterm effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376:1741-1750
15. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377:31-41
16. Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379:1602-1612
17. Burn J, Gerdes AM, Macrae F, et al.; CAPP2 Investigators. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011; 378:2081-2087
18. Cole BF, Logan RF, Halabi S, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 2009; 101:256-266
19. Bibbins-Domingo K; U.S. Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2016; 164:836-845
20. Ogawa H, Nakayama M, Morimoto T, et al.; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300:2134-2141
21. Saito Y, Okada S, Ogawa H, et al.; JPAD Trial Investigators. Low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus: 10-year follow-up of a randomized controlled trial. Circulation 2017; 135:659-670
22. Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 2013; 159: 77-85
23. Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol 2016; 27:2184-2195
24. Wang A, Aragaki AK, Tang JY, et al. Statin use and all-cancer survival: prospective results from the Women's Health Initiative. Br J Cancer 2016; 115:129-135
25. Baigent C, Blackwell L, Collins R, et al.; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373:1849-1860
26. Pignone M, Alberts MJ, Colwell JA, et al.; American Diabetes Association; American Heart Association; American College of Cardiology Foundation. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care 2010; 33: 1395-1402
27. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33:1674-1685
28. Dehmer SP, Maciosek MV, Flottemesch TJ, LaFrance AB, Whitlock EP. Aspirin for the primary prevention of cardiovascular disease and colorectal cancer: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2016; 164:777-786
29. Bray C, Bell LN, Liang H, Collins D, Yale SH. Colorectal cancer screening. WMJ 2017; 116: 27-33
30. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer 2009; 16:1103-1123
31. National Cancer Center, Center for Cancer Control and Information Services. Monitoring of Cancer Incidence in Japan (MCIJ) [Internet], 2013. Available from http://ganjoho.jp/data/reg-stat/statistics/brochure/mcij2013-report.pdf. Accessed 10 November 2017
32. Sasazuki S, Charvat H, Hara A, et al.; Research Group for the Development and Evaluation of Cancer Prevention Strategies in Japan. Diabetes mellitus and cancer risk: pooled analysis of eight cohort studies in Japan. Cancer Sci 2013; 104: 1499-1507
33. Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 2056-2062
34. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67:10804-10812
35. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: ameta-analysis. JAMA 2006; 295:74-80
36. Kuoppala J, Lamminpää A, Pukkala E. Statins and cancer: asystematicreview and meta-analysis. Eur J Cancer 2008; 44:2122-2132
37. McGlynn KA, Hagberg K, Chen J, et al. Statin use and risk of primary liver cancer in the Clinical Practice Research Datalink. J Natl Cancer Inst 2015; 107: djv009
38. Chen MJ, Tsan YT, Liou JM, et al. Statins and the risk of pancreatic cancer in type 2 diabetic patients-a population-based cohort study. Int J Cancer 2016; 138:594-603
39. Dulai PS, Singh S, Marquez E, et al. Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis. BMJ 2016; 355:i6188
40. Rydén L, Grant PJ, Anker SD, et al.; Authors / Task Force Members; ESC Committee for Practice Guidelines (CPG); Document Reviewers. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, prediabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34:3035-3087